ATYR Earnings & Financial Statements
aTyr Pharma, Inc.
$0.25
-$0.00(-0.43%)
33
Overall
60
Value
9
Tech
31
Quality
Market Cap
$25.04M
Volume
197.00K
52W Range
$0.27 - $1.12
Target Price
$2.75
ATYR earnings and financial statements: aTyr Pharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ATYR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10.39M | - |
| Operating income | -$77.63M | -$67.91M | -$54.92M | -$46.40M | -$34.02M |
| EBITDA | -$72.68M | -$62.49M | -$49.82M | -$44.06M | -$34.39M |
| Net income | -$74.12M | -$64.02M | -$50.39M | -$45.34M | -$33.77M |
| EPS (diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $93.00M | $96.83M | $120.65M | $95.79M | $115.54M |
| Total liabilities | $25.71M | $27.00M | $30.18M | $24.50M | $6.41M |
| Shareholders’ equity | $67.48M | $70.02M | $90.66M | $71.46M | $109.30M |
| Cash and equivalents | $10.74M | $11.05M | $22.54M | $9.98M | $2.34M |
| Long-term debt | $10.57M | $12.03M | $13.77M | $10.64M | $398.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$61.99M | -$69.12M | -$33.22M | -$41.89M | -$33.08M |
| Capital expenditure | -$65.0K | -$58.0K | -$4.20M | -$1.64M | -$192.0K |
| Free cash flow | -$62.06M | -$69.18M | -$37.44M | -$43.53M | -$33.27M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATYR | $0.25 | -0.4% | 197.00K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |